Sandeep Kiri has over thirteen years of experience in market access with a strong focus on health economics and health technology assessment. He has been in the global function at UCB for five years and is currently the Global Head of Health Economics and HTA Evidence with a keen focus on developing the right evidence for payers in order to demonstrate the full value of interventions.
Alexandre Templier has been working in the field of Life Sciences for more than 28 years. Passionate about Artificial Intelligence and data-driven decision-making in complex environments, Alexandre has dedicated his professional career to improving healthcare products and medical practice through Real World Data analytics and AI. Co-founder of Quinten Health and President of Quinten Health, he is particularly involved in the development of Quinten Health's activities within the healthcare sector (including projects for industry, healthcare providers, research institutions, and healthcare regulatory agencies). Alexandre was associate professor at Ecole Nationale Supérieure d'Arts & Métiers Paris Tech from 2001 to 2013.
Experienced leader in HEOR field with deep understanding of local and national payer’s needs, with a track record of unique initiatives which lead to sustainable impact for the brand, the companies, the HCPs and ultimately to the patients. Helene is driven by improving health management of chronic conditions/ oncology and optimizing treatment pathway by deep understand of health data and their use with internal and external governance.
Ralf has more than 30 years of experience in Data analysis, marketing and consulting for the pharmaceutical industry. In the course of his career, he has worked as an international consultant for many pharmaceutical companies with a focus on big data, statistics, analyses and return on investment. Ralf started his career at the US pharmaceutical manufacturing company Upjohn. He has been with Cegedim Health Data since 2020, having previously worked i.a. for IMS Health, Kantar Health, Cegedim Strategic Data and as High-Performance Coach. Graduating from the International Management School (Intermas), he holds an MBA and is a book author.
Dr. Michael Happich is Senior Director - Value Evidence Outcomes Intl - at Eli Lilly based in Bad Homburg, Germany. He leads an international team of HTA & RWE scientists to support drug launches, HTA submissions and observational research for autoimmune diseases outside the US. Before joining the industry 18 years ago, he worked at the Helmholtz-Research Center in Munich. He is lecturer on pharmacoeconomics at the Goethe University Frankfurt, and Neubrandenburg University of applied sciences.
